AU2019232736B2 - Adenosine receptor antagonists and uses thereof - Google Patents

Adenosine receptor antagonists and uses thereof Download PDF

Info

Publication number
AU2019232736B2
AU2019232736B2 AU2019232736A AU2019232736A AU2019232736B2 AU 2019232736 B2 AU2019232736 B2 AU 2019232736B2 AU 2019232736 A AU2019232736 A AU 2019232736A AU 2019232736 A AU2019232736 A AU 2019232736A AU 2019232736 B2 AU2019232736 B2 AU 2019232736B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
compound
alkyl
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019232736A
Other languages
English (en)
Other versions
AU2019232736A1 (en
Inventor
Elfatih Elzein
Jiwen Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teon Therapeutics Inc
Original Assignee
Teon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teon Therapeutics Inc filed Critical Teon Therapeutics Inc
Publication of AU2019232736A1 publication Critical patent/AU2019232736A1/en
Application granted granted Critical
Publication of AU2019232736B2 publication Critical patent/AU2019232736B2/en
Priority to AU2024204483A priority Critical patent/AU2024204483B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
AU2019232736A 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof Active AU2019232736B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204483A AU2024204483B2 (en) 2018-03-05 2024-06-28 Adenosine receptor antagonists and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638737P 2018-03-05 2018-03-05
US62/638,737 2018-03-05
US201862688088P 2018-06-21 2018-06-21
US62/688,088 2018-06-21
PCT/US2019/020810 WO2019173380A1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204483A Division AU2024204483B2 (en) 2018-03-05 2024-06-28 Adenosine receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
AU2019232736A1 AU2019232736A1 (en) 2020-10-08
AU2019232736B2 true AU2019232736B2 (en) 2024-05-02

Family

ID=67847428

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019232736A Active AU2019232736B2 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof
AU2024204483A Active AU2024204483B2 (en) 2018-03-05 2024-06-28 Adenosine receptor antagonists and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204483A Active AU2024204483B2 (en) 2018-03-05 2024-06-28 Adenosine receptor antagonists and uses thereof

Country Status (12)

Country Link
US (3) US20210040097A1 (https=)
EP (2) EP3762386B1 (https=)
JP (2) JP7849948B2 (https=)
KR (1) KR102754522B1 (https=)
CN (1) CN112218867B (https=)
AU (2) AU2019232736B2 (https=)
BR (1) BR112020018158A2 (https=)
ES (1) ES2975753T3 (https=)
IL (1) IL277144B2 (https=)
MX (1) MX2020009286A (https=)
SG (1) SG11202008611UA (https=)
WO (1) WO2019173380A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos
WO2022032091A1 (en) * 2020-08-07 2022-02-10 Teon Therapeutics, Inc. Combination therapy with adenosine receptor antagonists
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶
WO2022256550A1 (en) 2021-06-04 2022-12-08 Teon Therapeutics, Inc. Crystalline forms of an adenosine a2b receptor antagonist
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法
EP4554943A1 (en) * 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139428A1 (en) * 2001-11-09 2003-07-24 Rao Kalla A2B adenosine receptor antagonists
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
WO2007109547A2 (en) * 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
WO2009118759A2 (en) * 2008-03-26 2009-10-01 Advinus Therapeutics Pvt. Ltd., Heterocyclic compounds as adenosine receptor antagonist
WO2012003220A1 (en) * 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of a2b adenosine receptor antagonists for treating pulmonary hypertension

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
CA2323047C (en) * 1998-04-15 2005-03-15 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk, antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
HRP20040853A2 (en) * 2002-03-20 2004-12-31 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
MX2007002437A (es) * 2004-09-01 2007-08-14 Cv Therapeutics Inc Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b.
EP1799221A1 (en) 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
WO2008066627A2 (en) 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
WO2009157938A1 (en) 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CN103261200B (zh) * 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
AR085942A1 (es) * 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012170209A2 (en) * 2011-05-23 2012-12-13 Nectid, Inc. Benzofuran-2 carboxamide compounds
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
CN111093669A (zh) 2017-08-14 2020-05-01 法斯瑞斯公司 用于治疗癌症的腺苷受体拮抗剂的微颗粒制剂
CN111741752A (zh) 2017-12-19 2020-10-02 Gpcr治疗公司 Gpcr异聚体抑制剂及其用途
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139428A1 (en) * 2001-11-09 2003-07-24 Rao Kalla A2B adenosine receptor antagonists
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
WO2007109547A2 (en) * 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
WO2009118759A2 (en) * 2008-03-26 2009-10-01 Advinus Therapeutics Pvt. Ltd., Heterocyclic compounds as adenosine receptor antagonist
WO2012003220A1 (en) * 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of a2b adenosine receptor antagonists for treating pulmonary hypertension

Also Published As

Publication number Publication date
ES2975753T3 (es) 2024-07-12
KR102754522B1 (ko) 2025-01-13
US20210163483A1 (en) 2021-06-03
CN112218867B (zh) 2023-11-21
US20210040097A1 (en) 2021-02-11
AU2019232736A1 (en) 2020-10-08
IL277144B1 (en) 2024-02-01
JP7849948B2 (ja) 2026-04-22
JP2024032976A (ja) 2024-03-12
WO2019173380A1 (en) 2019-09-12
EP4364727A3 (en) 2024-05-15
AU2024204483B2 (en) 2026-04-02
EP3762386A1 (en) 2021-01-13
KR20200132901A (ko) 2020-11-25
IL277144B2 (en) 2024-06-01
US11124515B2 (en) 2021-09-21
EP3762386A4 (en) 2021-11-24
SG11202008611UA (en) 2020-10-29
CA3093234A1 (en) 2019-09-12
BR112020018158A2 (pt) 2021-02-02
JP2021517164A (ja) 2021-07-15
MX2020009286A (es) 2020-12-11
IL277144A (en) 2020-10-29
CN112218867A (zh) 2021-01-12
EP4364727A2 (en) 2024-05-08
AU2024204483A1 (en) 2024-07-18
US20220056033A1 (en) 2022-02-24
EP3762386B1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
AU2019232736B2 (en) Adenosine receptor antagonists and uses thereof
EP3466946B1 (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
KR20100017768A (ko) 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
EP1995240A1 (en) Quinolone derivative or pharmaceutically acceptable salt thereof
CA2567569A1 (en) Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton
JP2020502129A (ja) Ｎｒｆ２アクチベーターとしての３−オキソ−１，４−ジアゼピニル化合物
CA3037794A1 (en) Crystalline forms of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-t-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)piperazine-1-carboxylic acid butyl ester hydrochloride
TWI905181B (zh) 管腔作用之ｎ-(哌啶-4-基)苯甲醯胺衍生物
CA3093234C (en) Adenosine receptor antagonists and uses thereof
HK40108164A (en) Adenosine receptor antagonists and uses thereof
HK40041747B (en) Adenosine receptor antagonists and uses thereof
HK40041747A (en) Adenosine receptor antagonists and uses thereof
EA043897B1 (ru) Антагонисты аденозиновых рецепторов и их применения
WO2016019847A1 (zh) 一种氟代达比加群酯衍生物及其制备方法和在药学上的用途
JP2026074199A (ja) アデノシン受容体アンタゴニストおよびその使用
CN116531373B (zh) 噻唑类化合物、其药物组合物及应用
JP5983714B2 (ja) 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
CN116531381B (zh) 一种含硫类化合物及其药物组合物
CN117417301A (zh) 含硫类化合物、其药物组合物及应用
JP2645114B2 (ja) ロダニン誘導体
TW202600134A (zh) 一種多元螺環化合物的鹽及其晶型、其製備方法和醫藥用途
CN111848610B (zh) 一种吡啶衍生物的x晶型及其制备方法、用途
HK40004897B (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)